Skip to content

The role of intestinal bacteria in obese patients with cardiovascular risk (metabolic syndrome)

Role of the Intestinal Microbiota for management of Metabolic syndrome and Obesity - : Clinics Hospital of Univesity of Sao Paulo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2fm8j9
Enrollment
Unknown
Registered
2019-10-22
Start date
2018-01-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

Intervention: Intestinal microbiota transplant Collection of fecal material from volunteers with normal body mass index, material processing and bacterial isolation for endoscopic administration (uppe
Biological/vaccine
E02.095.231

Sponsors

Faculdade de Medicina da Universidade São Paulo
Lead Sponsor
Faculdade de Medicina da Universidade São Paulo
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Receivers: Caucasian women between the ages of 18 and 60 with a Body Mass Index (BMI) between 30 and 40 kg / m2 - obesity grade I and II - who meet the 2005 International Diabetes Federation (IDF) criteria for metabolic syndrome.

Exclusion criteria

Exclusion criteria: Receptors: patients with comorbidities that may interfere with data evaluation, use medications for metabolic syndrome, use antibiotics / pro-biotics in the past 90 days, previous cholecystectomy surgery, or have recent weight changes. Patients who refuse to participate in the study or who do not sign any of the terms of consent will also be excluded. Donors: donors who have received antibiotics for the last three months, who have risky sexual behavior

Design outcomes

Primary

MeasureTime frame
As a primary endpoint, the variation of the mean insulin sensitivity will be evaluated, and the secondary outcomes to be evaluated will be the effect of the intervention on the composition of the intestinal microbiota, glycemic and body mass indexes and other metabolic parameters described later. Increased insulin sensitivity is expected with improved glycemic control, change in faecal microbiota composition for transplanted bacteria, decreased BMI (weight loss) and improved metabolic parameters (calorimetry and bioimpedance)

Secondary

MeasureTime frame
Laboratory parameters: Sodium, potassium, calcium, ionic calcium, phosphorus, magnesium, urea, creatinine, AST, ALT, alkaline phosphatase, gamma-GT, total bilirubin and fractions, amylase, lipase, total cholesterol and fractions, triglycerides, glucose, insulin, glycosylated hemoglobin, total protein and fractions, folic acid, vitamin B12, ferritin, serum iron, transferrin, iron binding capacity, uric acid, platelet count, C-reactive protein, TSH, total T4, free T4, GH, IGF- ACTH, cortisol, SDHEA, FSH, LH, estradiol, progesterone, free testosterone, total testosterone, androstenedione, 17-alpha-hydroxyprogesterone, prolactin, parathormone, adiponectin and leptin. All the parameters will be obtained in the pre and post transplantation aiming to establish correlation between changes in the measured values and the possible changes in the composition of the fecal microbiota.

Countries

Brazil

Contacts

Public ContactAlberto da Ponte Neto

Faculdade de Medicina da Universidade São Paulo

albertomachadoneto@gmail.com+55-011-26616467

Outcome results

None listed

Source: REBEC (via WHO ICTRP)